Navigation Links
Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
Date:3/4/2008

AUSTIN, TX and TORONTO, March 4 /PRNewswire/ - Affinium Pharmaceuticals today announced that they have commenced the dosing of healthy subjects in a Phase I study of AFN-1252, one of its lead clinical candidates from its novel class of fatty acid biosyntheis inhibitors. The study of AFN-1252 will evaluate the safety, tolerability and pharmacokinetics of a single escalating oral dose. Affinium believes that AFN-1252 will provide patients and their doctors a potent, oral and IV treatment for susceptible and resistant staphylococcal infections both in and out of hospitals.

AFN-1252 is an investigational antibiotic, with a novel mechanism of action, and very high potency against all drug-resistant phenotpyes of staphylococci including hospital and community-acquired MRSA. Oral bioavailability has previously been demonstrated in a human microdosing study and excellent in vivo efficacy has been demonstrated in various animal models of infection.

"Affinium is very pleased to advance this novel class of antibiotics with great potential to address the serious unmet medical need for new oral and IV antibiotics capable of treating multi-drug resistant staphylococcal infections," said Dr. Barry Hafkin, Chief Medical Officer of Affinium Pharmaceuticals. "In preclinical studies, AFN-1252 was well tolerated at high multiples of the projected human dose in two species, suggesting a safety profile that would be very attractive to physicians practicing both in and out of hospital settings." Dr. Hafkin added that "the specific-spectrum of activity of AFN-1252 may provide further safety advantages by decreasing the risk of gut and cutaneous flora disruption."

About Affinium Pharmaceuticals

Affinium Pharmaceuticals is a specialty pharmaceutical company focused on the discovery, development and commercialization of novel anti-infective medicines. AFN-1252 utilizes a unique mechanism of action by directly inhibiting the function of the bacterial fatty ac
'/>"/>

SOURCE Affinium Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
2. Renhuang Pharmaceuticals, Inc. Retains CCG Elite
3. Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies
4. Jazz Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 13, 2008
5. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
6. Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR
7. Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR
8. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
9. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
10. American Stock Exchange LLC to Delist Securities of Samaritan Pharmaceuticals, Inc.
11. Law Offices of Howard G. Smith Announces 25 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Threshold Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... ... As more hospitals across the country see the value in developing their ... of growing competition, it is more important than ever to market a hospital’s ... at Wound Care Advantage has found that while many hospitals already have ...
(Date:7/30/2015)... ... ... OSF Healthcare System has been recognized as one of the nation’s ... & Health Networks. This marks the fourth consecutive year for this achievement by the ... Third Order of St. Francis . , Health data security and patient engagement are ...
(Date:7/30/2015)... ... ... between a healthy head of hair and a feeling of confidence is a powerful one ... have a devastating impact on the daily life of a person. From increased anxiety ... hair loss are not to be taken lightly. , The skilled staff at Parsa Mohebi ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zaca Life has ... go. With no water needed, the refreshing berry-flavored tablets are the perfect travel ... the natural ingredients that may help with body detoxification, protection and hydration,” said ...
(Date:7/30/2015)... FL (PRWEB) , ... July 30, 2015 , ... ... software, TikiLIVE, has worked to protect victims in San Diego, California’s Gaslamp Quarter ... used by Gaslamp Quarter Plaza actively monitor the area for any suspicious ...
Breaking Medicine News(10 mins):Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 4Health News:OSF HealthCare Named One of the Most Wired Systems 2Health News:OSF HealthCare Named One of the Most Wired Systems 3Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3
... eye cancer is greater among kidney transplant patients and ... public, which suggests the disease is associated with immune ... of New South Wales in Sydney and colleagues compared ... general population with that of kidney transplant patients, who ...
... apo A-I ratio is not a better predictor of ... include total cholesterol and HDL-C, according to a study ... risk-prediction instruments and guidelines for coronary heart disease (CHD) ... total cholesterol, or both for CHD risk assessment. But ...
... parents informational handouts can improve their understanding of the ... according to a recent study conducted by researchers from ... School of Medicine in New Haven, CT. , Like ... about the increasing radiation exposure to children caused by ...
Frederic Geissmann and colleagues find that Langerhans cell accumulation in Langerhans cell histiocytosis results from survival rather than uncontrolled proliferation, and is associated with the expan...
... tell us when middle-aged spread is getting out of hand. ... the ready. New research shows that adding several inches to ... rangemarkedly increases the risk of unhealthy plaque build-up in the ... , The research, conducted at the University of Texas Southwestern ...
... indicates that the loss of two types of brain ... of symptoms associated with Parkinson,s disease. , The evidence, ... loss of both norepinephrine and dopamine neurons and the ... was originally thought that the loss of only dopamine ...
Cached Medicine News:Health News:Use of certain lipid measures not more effective in predicting coronary heart disease 2Health News:Informational handout key to giving parents a better understanding of CT radiation risks 2Health News:Pot bellies linked to early signs of cardiovascular disease 2Health News:Pot bellies linked to early signs of cardiovascular disease 3Health News:Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinson's symptoms 2
(Date:7/30/2015)... special edition of #MedicareMonday on Medicare,s 50 th anniversary. As Medicare celebrates 50 ... highlighting the success of the prescription drug benefit, commonly referred to as Part D. ... and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)... -- Amgen (NASDAQ: AMGN ) today announced financial ... results include: , Total revenues increased 4 ... $5,370 million, with 6 percent product sales growth ... ® (denosumab), Sensipar ® (cinacalcet), Kyprolis ... Unfavorable changes in foreign exchange rates impacted total ...
(Date:7/30/2015)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... the notice it received on May 21, 2015 from ... Company was below certain of the Exchange,s continued listing ... of the NYSE MKT Company Guide, due to the ...
Breaking Medicine Technology:Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... announces that a new market research report is ... Optoelectronics Industry http://www.reportlinker.com/p087331/Global-Optoelectronics-Industry.html ... for Optoelectronics in Millions of US$ by the ... Optical Components. Major segments analyzed under the Optical ...
... Inc. (Pink Sheets: SNDY ) is pleased ... meeting held September 28, 2010 near Solos, headquarters in ... Amanda Segersten and Fred Schiemann were re-elected to serve ... shareholders meeting. The shareholders also approved the motion to ...
Cached Medicine Technology:Reportlinker Adds Global Optoelectronics Industry 2Reportlinker Adds Global Optoelectronics Industry 3Reportlinker Adds Global Optoelectronics Industry 4Reportlinker Adds Global Optoelectronics Industry 5Reportlinker Adds Global Optoelectronics Industry 6Reportlinker Adds Global Optoelectronics Industry 7Reportlinker Adds Global Optoelectronics Industry 8Reportlinker Adds Global Optoelectronics Industry 9Reportlinker Adds Global Optoelectronics Industry 10Reportlinker Adds Global Optoelectronics Industry 11Reportlinker Adds Global Optoelectronics Industry 12Reportlinker Adds Global Optoelectronics Industry 13Reportlinker Adds Global Optoelectronics Industry 14Reportlinker Adds Global Optoelectronics Industry 15Reportlinker Adds Global Optoelectronics Industry 16Reportlinker Adds Global Optoelectronics Industry 17Reportlinker Adds Global Optoelectronics Industry 18Reportlinker Adds Global Optoelectronics Industry 19Reportlinker Adds Global Optoelectronics Industry 20Reportlinker Adds Global Optoelectronics Industry 21Reportlinker Adds Global Optoelectronics Industry 22Reportlinker Adds Global Optoelectronics Industry 23Reportlinker Adds Global Optoelectronics Industry 24Reportlinker Adds Global Optoelectronics Industry 25Solos Endoscopy, Inc. Announces Results of 2010 Annual Shareholder Meeting 2
One step Immunochromatographic Assay for the detection of Respiratory Syncytial Virus...
Rapid Immunoassay for the detection of Respiratory Syncytial Virus....
Rapid, visual assay for the presumptive qualitative detection of Respiratory Syncytial Virus (RSV) directly from nasopharyngeal specimens in neonatel and pediatric patients....
... utilizes a new, improved format that requires only ... detection. The testing device employs innovative lateral flow ... already been applied to the testing strip. Workflow ... results shown by the appearance of an easy-to-read ...
Medicine Products: